Dexamethasone nanomedicines for COVID-19

Twan Lammers*, Alexandros Marios Sofias, Roy van der Meel, Raymond Schiffelers, Gert Storm, Frank Tacke, Steffen Koschmieder, Tim H. Brümmendorf, Fabian Kiessling, Josbert M. Metselaar

*Corresponding author for this work

Research output: Contribution to journalComment/Letter to the editorAcademicpeer-review

129 Citations (Scopus)
28 Downloads (Pure)


Nano-formulating dexamethasone, and administering it via intravenous injection or inhalation, may help to improve anti-COVID-19 treatment efficacy by targeting the potent corticosteroid drug to hyper-activated immune cells, by potentiating its anti-oedema activity and by exploiting its anti-fibrotic effects.
Original languageEnglish
Pages (from-to)622-624
Number of pages3
JournalNature nanotechnology
Issue number8
Publication statusPublished - 3 Aug 2020


  • 22/2 OA procedure


Dive into the research topics of 'Dexamethasone nanomedicines for COVID-19'. Together they form a unique fingerprint.

Cite this